glp-1 obesity drugs analogs, new trend in treatment, become even more effective < Pharma < Article Upcoming wave of hormone-based therapies

doi: 10.1161/CIRCRESAHA.118.313591

Viking Therapeutics Today VKTX Viking Therapeutics $37.08 +0.71 (+1.95%) As of 07/17/2026 04:00 PM Eastern 52-Week Range $22.96 $43.15 Price Target $93.60 Viking is developing VK2735 in both oral and injectable forms and should begin Phase 3 trials for the oral form in the coming months

Start feeling better faster with a formula that promotes overall wellness and helps you stay on track with your therapy

Slowing the gut brings nausea, constipation, and reflux

Saxenda is administered once a day by subcutaneous injection

GLP-1 is a hormone released from the gut after meals that: Stimulates insulin release when blood sugar is high Reduces glucagon levels Slows stomach emptying Signals satiety to the brain Modern GLP-1based medications (semaglutide alone and tirzepatide as a dual GIP/GLP-1 agonist) mimic or combine these effects